BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Ltd. $69.1 Series B Andera Partners, Biodiscovery, Quan Capital, Quan Ventures, Sofinnova Partners, IP Group, EMBL Ventures...
BioCentury | Sep 14, 2018
Company News

Boehringer to acquire oncolytic virus company ViraTherapeutics

...virus program, for which Boehringer was responsible for R&D costs. Boehringer Ingelheim Venture Fund and EMBL Ventures...
BioCentury | Sep 13, 2018
Company News

Boehringer adds to immuno-oncology pipeline with ViraTherapeutics acquisition

...virus program, for which Boehringer was responsible for R&D costs. Boehringer Ingelheim Venture Fund and EMBL Ventures...
BioCentury | Apr 28, 2017
Financial News

Arsanis completes venture financing

...GV and Alexandria Venture Investments. Existing investors OrbiMed, Polaris Venture Partners, SV Health Investors, NeoMed, EMBL Ventures...
BioCentury | Apr 26, 2017
Financial News

Gates Foundation leads Arsanis' $45.5M series D

...Venture Investments, as well as existing investors OrbiMed, Polaris Venture Partners, SV Health Investors, NeoMed, EMBL Ventures...
BioCentury | Sep 28, 2016
Company News

Boehringer, ViraTherapeutics in oncolytic virus deal

...the first close of a series A round co-led by Boehringer Ingelheim Venture Fund and EMBL Ventures. BC...
BioCentury | Jun 20, 2016
Financial News

Allecra completes venture financing

...EUR22 million ($24.8 million) Investors: Delos Capital; Forbion Capital Partners; Edmond de Rothschild Investment Partners; EMBL Ventures...
BioCentury | Jun 16, 2016
Financial News

Antibiotic play Allecra raises EUR 22M

...by new investor Delos Capital. Existing investors Forbion Capital Partners, Edmond de Rothschild Investment Partners, EMBL Ventures...
BioCentury | May 9, 2016
Emerging Company Profile

Deliver to the liver

...million ($15.8 million) in the first close of a series A round from Epidarex Capital, EMBL Ventures...
...partners: None Number of employees: 4 Funds raised: €14 million ($15.8 million) Investors: Epidarex Capital, EMBL Ventures...
BioCentury | Mar 28, 2016
Finance

Back in the game

...product after Phase I testing. Epidarex Capital led the series A and was joined by EMBL Ventures...
Items per page:
1 - 10 of 41
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Ltd. $69.1 Series B Andera Partners, Biodiscovery, Quan Capital, Quan Ventures, Sofinnova Partners, IP Group, EMBL Ventures...
BioCentury | Sep 14, 2018
Company News

Boehringer to acquire oncolytic virus company ViraTherapeutics

...virus program, for which Boehringer was responsible for R&D costs. Boehringer Ingelheim Venture Fund and EMBL Ventures...
BioCentury | Sep 13, 2018
Company News

Boehringer adds to immuno-oncology pipeline with ViraTherapeutics acquisition

...virus program, for which Boehringer was responsible for R&D costs. Boehringer Ingelheim Venture Fund and EMBL Ventures...
BioCentury | Apr 28, 2017
Financial News

Arsanis completes venture financing

...GV and Alexandria Venture Investments. Existing investors OrbiMed, Polaris Venture Partners, SV Health Investors, NeoMed, EMBL Ventures...
BioCentury | Apr 26, 2017
Financial News

Gates Foundation leads Arsanis' $45.5M series D

...Venture Investments, as well as existing investors OrbiMed, Polaris Venture Partners, SV Health Investors, NeoMed, EMBL Ventures...
BioCentury | Sep 28, 2016
Company News

Boehringer, ViraTherapeutics in oncolytic virus deal

...the first close of a series A round co-led by Boehringer Ingelheim Venture Fund and EMBL Ventures. BC...
BioCentury | Jun 20, 2016
Financial News

Allecra completes venture financing

...EUR22 million ($24.8 million) Investors: Delos Capital; Forbion Capital Partners; Edmond de Rothschild Investment Partners; EMBL Ventures...
BioCentury | Jun 16, 2016
Financial News

Antibiotic play Allecra raises EUR 22M

...by new investor Delos Capital. Existing investors Forbion Capital Partners, Edmond de Rothschild Investment Partners, EMBL Ventures...
BioCentury | May 9, 2016
Emerging Company Profile

Deliver to the liver

...million ($15.8 million) in the first close of a series A round from Epidarex Capital, EMBL Ventures...
...partners: None Number of employees: 4 Funds raised: €14 million ($15.8 million) Investors: Epidarex Capital, EMBL Ventures...
BioCentury | Mar 28, 2016
Finance

Back in the game

...product after Phase I testing. Epidarex Capital led the series A and was joined by EMBL Ventures...
Items per page:
1 - 10 of 41